Fatty Liver Disease
Long-term rosiglitazone improves the markers of nonalcoholic steatohepatitis
Published in Hepatitis Weekly, December 1st, 2003
"Insulin resistance (IR) commonly is associated with nonalcoholic steatoliepatitis (NASH). To establish whether IR causes NASH, this study was undertaken to determine if improving IR would improve the histologic features that define NASH. Thirty adults with prior biopsy evidence of NASH were enrolled to receive rosiglitazone, 4 mg twice daily for 48 weeks," scientists in the United States report.
"All patients were overweight (body mass index [BMI] > 25 kg/m2) and 23% were severely obese (BMI > 35 kg/m2); 50% had impaired glucose tolerance or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2003-12-01)
More Articles from Hepatitis Weekly
- Endocrinology
Interferon improves insulin dynamics in chronic hepatitis B and C responders - Stem-Cell Research
Bone marrow-derived cells offer little hope for repairing damaged livers - Addiction Medicine
Methadone users need access to orthotopic liver transplantations - Pain Medicine
Patients with liver diseases report having upper abdominal pain symptoms - Transplantation
Where livers and kidneys are both needed liver transplants should be done first - Addiction Medicine
Patients with alcoholic etiologies fare worse in a study of steatohepatitis - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
